DK1663315T3 - Lipid-lægemiddelformuleringer til målrettet farmakoterapi af myeloide og lymfoide immunceller - Google Patents

Lipid-lægemiddelformuleringer til målrettet farmakoterapi af myeloide og lymfoide immunceller

Info

Publication number
DK1663315T3
DK1663315T3 DK04784440.2T DK04784440T DK1663315T3 DK 1663315 T3 DK1663315 T3 DK 1663315T3 DK 04784440 T DK04784440 T DK 04784440T DK 1663315 T3 DK1663315 T3 DK 1663315T3
Authority
DK
Denmark
Prior art keywords
cell
myeloid
lipid
immune cells
drug formulations
Prior art date
Application number
DK04784440.2T
Other languages
English (en)
Inventor
Sean M Sullivan
Robert K Gieseler
Guido Marquitan
Michael J Scolaro
Original Assignee
Rodos Biotarget Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rodos Biotarget Gmbh filed Critical Rodos Biotarget Gmbh
Application granted granted Critical
Publication of DK1663315T3 publication Critical patent/DK1663315T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Botany (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK04784440.2T 2003-09-17 2004-09-17 Lipid-lægemiddelformuleringer til målrettet farmakoterapi af myeloide og lymfoide immunceller DK1663315T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50376903P 2003-09-17 2003-09-17
US56737604P 2004-04-30 2004-04-30
PCT/US2004/030578 WO2005027979A2 (en) 2003-09-17 2004-09-17 Targeted lipid-drug formulations for delivery of drugs to myeloid and lymphoid immune cells

Publications (1)

Publication Number Publication Date
DK1663315T3 true DK1663315T3 (da) 2011-04-18

Family

ID=34381085

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04784440.2T DK1663315T3 (da) 2003-09-17 2004-09-17 Lipid-lægemiddelformuleringer til målrettet farmakoterapi af myeloide og lymfoide immunceller

Country Status (8)

Country Link
US (3) US20050142114A1 (da)
EP (1) EP1663315B1 (da)
JP (1) JP2007505925A (da)
AT (1) ATE494011T1 (da)
CA (1) CA2539256C (da)
DE (1) DE602004030923D1 (da)
DK (1) DK1663315T3 (da)
WO (1) WO2005027979A2 (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7233340B2 (en) * 2003-02-27 2007-06-19 Applied Imaging Corp. Linking of images to enable simultaneous viewing of multiple objects
ES2388531T3 (es) 2004-03-19 2012-10-16 Rodos Biotarget Gmbh Liposomas derivatizados con hidratos de carbono para la selección como diana de dominios de reconocimiento de hidratos de carbono celulares de lectinas CTL/CTLD y suministro intracelular de compuestos terapéuticamente activos
AU2005306533B2 (en) * 2004-11-17 2012-05-31 Arbutus Biopharma Corporation siRNA silencing of apolipoprotein B
WO2007047539A2 (en) * 2005-10-14 2007-04-26 Medtronic, Inc. Localized delivery to the lymphatic system
US8138160B2 (en) * 2006-08-03 2012-03-20 Warsaw Orthopedic, Inc. Reagents, methods and systems to suppress pro-inflammatory cytokines
EP2058009A4 (en) * 2006-08-31 2009-10-28 Astellas Pharma Inc REVERSE TARGETING-lipid vesicles
TWI428135B (zh) * 2007-03-26 2014-03-01 Hirofumi Takeuchi And a carrier composition for quick-acting nucleic acid delivery
WO2010045479A1 (en) * 2008-10-15 2010-04-22 The Board Of Trustees Of The University Of Illinois Phospholipid micellar and liposomal compositions and uses thereof
CA2764158A1 (en) 2009-06-01 2010-12-09 Halo-Bio Rnai Therapeutics, Inc. Polynucleotides for multivalent rna interference, compositions and methods of use thereof
WO2011109809A2 (en) * 2010-03-05 2011-09-09 New Agriculture, Inc A novel composition of matter for delivering lipid-soluble materials, and a method for producing it
WO2012094004A1 (en) * 2011-01-05 2012-07-12 The United States Of America, As Represented By The Secretary Of Agriculture Fusion of peptidoglycan hydrolase enzymes to a protein transduction domain allows eradication of both extracellular and intracellular gram positive pathogens
US20140087395A1 (en) * 2011-03-31 2014-03-27 Hiroshima University Method for distinguishing between species within the genus staphilococcus
EP2638896A1 (en) 2012-03-14 2013-09-18 Bioneer A/S Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood
WO2014153114A1 (en) 2013-03-14 2014-09-25 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
US20140271815A1 (en) * 2013-03-15 2014-09-18 Aryo Sorayya Heat-and freeze-stable vaccines and methods of making and using same
US9603799B2 (en) 2013-03-15 2017-03-28 Htd Biosystems Inc. Liposomal vaccine adjuvants and methods of making and using same
US10427124B2 (en) * 2013-09-19 2019-10-01 Nanyang Technological University Methods for controlling assembly of lipids on a solid support
BR112018003784A2 (pt) 2015-08-24 2018-09-25 Halo-Bio Rnai Therapeutics, Inc. nanopartículas de polinucleotídeo para a modulação da expressão gênica e sua utilização
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
US11566061B2 (en) 2017-01-05 2023-01-31 Fred Hutchinson Cancer Center Systems and methods to improve vaccine efficacy
WO2020089811A1 (en) 2018-10-31 2020-05-07 Novartis Ag Dc-sign antibody drug conjugates
WO2022040435A1 (en) * 2020-08-19 2022-02-24 The Board Of Regents Of The University Of Texas System Nanodrugs for targeted drug delivery and use thereof
WO2024026452A1 (en) 2022-07-29 2024-02-01 Repertoire Immune Medicines, Inc. T cell epitopes associated with type 1 diabetes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4795739A (en) * 1987-05-29 1989-01-03 Gene Labs, Inc. Method of inhibiting HIV
AU652006B2 (en) * 1990-10-09 1994-08-11 Nexstar Pharmaceuticals, Inc. Inhibition of viral replication
GB9317380D0 (en) * 1993-08-20 1993-10-06 Therexsys Ltd Transfection process
US7780882B2 (en) * 1999-02-22 2010-08-24 Georgetown University Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent
CA2270600A1 (en) * 1999-05-03 2000-11-03 Infectio Recherche Inc. Method and formulations for the treatment of diseases, particularly those caused by human immunodeficiency virus and leishmania
CA2474056A1 (en) * 2002-01-24 2003-07-31 Sangstat Medical Corporation Combination therapy for treatment of hiv infection
US20040248296A1 (en) * 2002-03-20 2004-12-09 Beresford Paul J. HIV therapeutic
US20040208921A1 (en) * 2003-01-14 2004-10-21 Ho Rodney J. Y. Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues

Also Published As

Publication number Publication date
US20160324779A1 (en) 2016-11-10
EP1663315B1 (en) 2011-01-05
CA2539256A1 (en) 2005-03-31
JP2007505925A (ja) 2007-03-15
ATE494011T1 (de) 2011-01-15
US20140234400A1 (en) 2014-08-21
US20050142114A1 (en) 2005-06-30
US10357457B2 (en) 2019-07-23
WO2005027979A3 (en) 2005-09-09
DE602004030923D1 (de) 2011-02-17
CA2539256C (en) 2012-04-24
EP1663315A2 (en) 2006-06-07
WO2005027979A2 (en) 2005-03-31

Similar Documents

Publication Publication Date Title
DK1663315T3 (da) Lipid-lægemiddelformuleringer til målrettet farmakoterapi af myeloide og lymfoide immunceller
Timaner et al. Therapy-educated mesenchymal stem cells enrich for tumor-initiating cells
Zhang et al. Macrophage-derived IL-1α promotes sterile inflammation in a mouse model of acetaminophen hepatotoxicity
Wang et al. mRNA delivery of a bispecific single‐domain antibody to polarize tumor‐associated macrophages and synergize immunotherapy against liver malignancies
Cunha et al. The role of the inflammatory microenvironment in thyroid carcinogenesis
Tan et al. Lysyl oxidase‐like 4 fosters an immunosuppressive microenvironment during hepatocarcinogenesis
Cheng et al. Engineered mesenchymal stem cells for targeting solid tumors: therapeutic potential beyond regenerative therapy
Herrmann et al. TLR9 is critical for glioma stem cell maintenance and targeting
Bansal et al. Selective targeting of interferon γ to stromal fibroblasts and pericytes as a novel therapeutic approach to inhibit angiogenesis and tumor growth
Schiaffo et al. Structure–activity relationship analysis of imidazoquinolines with Toll-like receptors 7 and 8 selectivity and enhanced cytokine induction
Kobayashi et al. Halothane-induced liver injury is mediated by interleukin-17 in mice
Zhang et al. Hepatitis B–Induced IL8 Promotes Hepatocellular Carcinoma Venous Metastasis and Intrahepatic Treg Accumulation
Kyritsi et al. Mast cells induce ductular reaction mimicking liver injury in mice through mast cell–derived transforming growth factor beta 1 signaling
Xu et al. Runx2 deficiency in osteoblasts promotes myeloma progression by altering the bone microenvironment at new bone sites
Delforoush et al. In vitro and in vivo activity of melflufen (J1) in lymphoma
Hu et al. A novel TLR7 agonist as adjuvant to stimulate high quality HBsAg-specific immune responses in an HBV mouse model
Lu et al. Integrated two‐analyte population pharmacokinetic model of polatuzumab vedotin in patients with non‐Hodgkin lymphoma
Prijovich et al. Synthesis and antitumor properties of BQC-glucuronide, a camptothecin prodrug for selective tumor activation
Jensen et al. Tumoricidal effects of macrophage-activating immunotherapy in a murine model of relapsed/refractory multiple myeloma
Zhou et al. Targeting peripheral immune organs with self‐assembling prodrug nanoparticles ameliorates allogeneic heart transplant rejection
Kim et al. Bioimaging of Hyaluronate–Interferon α Conjugates Using a Non-Interfering Zwitterionic Fluorophore
Naito et al. IL-17A activated by Toll-like receptor 9 contributes to the development of septic acute kidney injury
Di Stefano et al. Liver‐targeted doxorubicin: effects on rat regenerating hepatocytes
Ota et al. Novel intravenous injectable TLR7 agonist, DSP-0509, synergistically enhanced antitumor immune responses in combination with anti-PD-1 antibody
Bao et al. Inhibition of Poly (ADP-ribose) Polymerase Sensitizes [177Lu] Lu-DOTAGA.(SA. FAPi) 2-Mediated Radiotherapy in Triple-Negative Breast Cancer